Caribou Biosciences, Inc. (CRBU): Price and Financial Metrics

Caribou Biosciences, Inc. (CRBU): $4.81

-0.07 (-1.43%)

POWR Rating

Component Grades













Add CRBU to Watchlist
Sign Up

Industry: Biotech



in industry


  • CRBU scores best on the Value dimension, with a Value rank ahead of 69.07% of US stocks.
  • CRBU's strongest trending metric is Value; it's been moving up over the last 178 days.
  • CRBU's current lowest rank is in the Momentum metric (where it is better than 4.74% of US stocks).

CRBU Stock Summary

  • CARIBOU BIOSCIENCES INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 11.26% of US listed stocks.
  • CRBU's went public 1.66 years ago, making it older than only 3.54% of listed US stocks we're tracking.
  • CRBU's price/sales ratio is 21.95; that's higher than the P/S ratio of 94.69% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CARIBOU BIOSCIENCES INC are CRIS, MCRB, GWH, CRDF, and AGLE.
  • To check out CARIBOU BIOSCIENCES INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001619856.

CRBU Valuation Summary

  • In comparison to the median Healthcare stock, CRBU's price/sales ratio is 365.96% higher, now standing at 21.9.
  • CRBU's price/sales ratio has moved down 45.7 over the prior 20 months.

Below are key valuation metrics over time for CRBU.

Stock Date P/S P/B P/E EV/EBIT
CRBU 2023-03-17 21.9 1.0 -3.1 -2.8
CRBU 2023-03-16 22.3 1.0 -3.1 -2.8
CRBU 2023-03-15 22.8 1.1 -3.2 -2.9
CRBU 2023-03-14 23.0 1.1 -3.2 -2.9
CRBU 2023-03-13 23.6 1.1 -3.3 -3.0
CRBU 2023-03-10 22.9 1.1 -3.2 -2.9

CRBU Price Target

For more insight on analysts targets of CRBU, see our CRBU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.67 Average Broker Recommendation 1.33 (Strong Buy)

CRBU Stock Price Chart Interactive Chart >

Price chart for CRBU

CRBU Price/Volume Stats

Current price $4.81 52-week high $13.19
Prev. close $4.88 52-week low $4.72
Day low $4.77 Volume 372,892
Day high $4.99 Avg. volume 469,783
50-day MA $6.41 Dividend yield N/A
200-day MA $8.14 Market Cap 294.85M

Caribou Biosciences, Inc. (CRBU) Company Bio

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

CRBU Latest News Stream

Event/Time News Detail
Loading, please wait...

CRBU Latest Social Stream

Loading social stream, please wait...

View Full CRBU Social Stream

Latest CRBU News From Around the Web

Below are the latest news stories about CARIBOU BIOSCIENCES INC that investors may wish to consider to help them evaluate CRBU as an investment opportunity.

Caribou Biosciences Full Year 2022 Earnings: Beats Expectations

Caribou Biosciences ( NASDAQ:CRBU ) Full Year 2022 Results Key Financial Results Revenue: US$13.9m (up 44% from FY...

Yahoo | March 11, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of the week with a breakdown of the biggest pre-market stock movers worth watching on Friday!

William White on InvestorPlace | March 10, 2023

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses Revenue Estimates

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 6.38% and 2.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 10, 2023

Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

-- CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 -- -- CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 -- -- $317.0 million in cash, cash equivalents, and marketable securities as of December 31, 2022; cash runway to fund the current operating plan into 2025 -- BERKELEY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (N

Yahoo | March 9, 2023

Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

BERKELEY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to participate in a fireside chat at the virtual Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:40 am EDT. Register for the live webcast by visiting the Events page on Caribou’s website. The webcast will be

Yahoo | March 8, 2023

Read More 'CRBU' Stories Here

CRBU Price Returns

1-mo -29.78%
3-mo -26.11%
6-mo -52.94%
1-year -47.43%
3-year N/A
5-year N/A
YTD -23.41%
2022 -58.38%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7801 seconds.